Ketamine's Effects on Insomnia and Suicidal Ideation at Doses Below 0.5mg/kg

Effects on Suicidal Ideation

• Ketamine at doses of 0.2-0.5 mg/kg has demonstrated rapid reduction in suicidal ideation across multiple studies, with effects beginning as quickly as 40 minutes post-administration 1, 2
• Lower doses (0.2 mg/kg) administered in emergency department settings have shown significant reductions in suicidal ideation for up to 10 days following infusion 1
• The antisuicidal effects of ketamine may be partially independent of its general antidepressant effects, though this requires further investigation 2

Effects on Sleep and Insomnia

• At doses below 0.5 mg/kg, ketamine has not been specifically associated with insomnia in the available evidence 3, 4
• The most recent and highest quality evidence indicates that ketamine at minimal doses (0.015 mg/kg/h infusion without bolus) does not significantly increase delirium or sleep disturbances compared to placebo 3, 5
• Higher doses of ketamine (0.25-0.5 mg/kg) are more likely to cause psychotomimetic effects that could potentially disrupt sleep, including hallucinations and nightmares 3, 5

Dose-Dependent Side Effects

• Psychotomimetic effects of ketamine appear to be dose-dependent, with higher incidence at doses approaching or exceeding 0.5 mg/kg 3, 5
• In a three-arm randomized controlled trial, patients receiving low-dose ketamine (0.25 mg/kg bolus and 0.125 mg/kg/h infusion) had significantly higher delirium scores than both minimal-dose ketamine and placebo groups 3, 5
• The PODCAST trial found that ketamine at doses of 0.5 mg/kg and 1.0 mg/kg increased the incidence of hallucinations (20% and 28% respectively vs. 18% for placebo) and nightmares (12% and 15% respectively vs. 8% for placebo) 5

Clinical Implications

• For patients requiring treatment for suicidal ideation, lower ketamine doses (0.2-0.25 mg/kg) may provide antisuicidal benefits while minimizing psychotomimetic effects 1

Ketamine for Treatment-Resistant Depression

Mechanism of Action and Pharmacology

• Ketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist that produces rapid antidepressant effects in both unipolar and bipolar treatment-resistant depression 6
• The standard protocol for intravenous administration is 0.5 mg/kg infused over 40 minutes, though other routes of administration have been studied 7

Efficacy in Treatment-Resistant Depression

Antisuicidal Effects

• Ketamine produces rapid reductions in suicidal ideation (SI) across multiple rating scales, with effects beginning as quickly as 40 minutes post-infusion 6, 8
• Effect sizes for SI reduction are largest at 40 minutes (d=1.05), diminishing to moderate effect sizes at 230 minutes (d=0.45) 8, 7
• In patients with high baseline SI, effect sizes are substantially larger (d=2.36 at 40 minutes and d=1.27 at 230 minutes) 8, 7
• Some evidence suggests ketamine's antisuicidal effects may be independent of its general antidepressant effects 9

Administration Protocols

Intravenous Administration

• Standard protocol: 0.5 mg/kg infused over 40 minutes 6, 7

Clinical Applications and Considerations

• Ketamine should be considered for patients with TRD who have failed at least two adequate trials of antidepressants 6
• Particularly valuable for patients with acute suicidal ideation given its rapid onset of action 6, 9

Emergency Department Applications

• Ketamine shows promise for rapid reduction of suicidal ideation in emergency department settings 9
• Lower doses (0.2 mg/kg over 1-2 minutes) have shown significant reductions in SI for up to 10 days following infusion 9
• May provide a bridge treatment for acutely suicidal patients until traditional treatments take effect 6, 9

Ketamine Use in Bipolar Disorder

Evidence-Based Recommendations

• The American College of Physicians and other guideline societies support ketamine/esketamine for treatment-resistant depression, with 61% response rates and rapid reduction in suicidal ideation, as add-on therapy to mood stabilizers (lithium or valproate) to mitigate manic switch risk 10, 11
• The 2022 VA/DoD guidelines now support ketamine/esketamine for treatment-resistant depression, representing a significant shift from the 2016 recommendation against use outside research settings 10, 11

Efficacy and Safety

• Ketamine produces rapid and robust reduction in suicidal ideation in bipolar depression, with effects beginning within 40 minutes and may be partially independent of general antidepressant effects 12
• The VA/DoD guidelines specifically support ketamine for short-term reduction in suicidal ideation in patients with MDD and suicidal ideation 10, 11
• Antidepressant effects persist for 2-3 days after single infusion, and improvements remain significant through day 7 when ketamine is added to ongoing antidepressant treatment 10, 11

Tolerability and Side Effects

• Esketamine requires Risk Evaluation and Mitigation Strategy (REMS) certification and mandatory 2-hour post-treatment monitoring 10, 11

Clinical Implementation

• Verify treatment resistance: at least 2 adequate antidepressant trials have failed, before initiating ketamine as add-on therapy to mood stabilizers (lithium or valproate) 10, 11

Key Limitations and Gaps

• Long-term efficacy and safety data remain limited, with most evidence coming from small sample sizes 10, 11
• Optimal maintenance strategies are not well-established, and the effectiveness of esketamine in preventing suicide has not been established despite FDA approval for acute suicidal ideation 10, 11, 13

Evidence-Based Protocol for IV Ketamine in Depression

Patient Selection and Treatment Protocol

• The American Psychiatric Association recommends IV ketamine for treatment-resistant depression, administering 0.5 mg/kg infused over 40 minutes, which is the standard evidence-based protocol supported by multiple studies 14
• Patients with acute suicidal ideation may benefit from IV ketamine due to its rapid onset of action, with effects beginning within 40 minutes 14
• IV ketamine can be used in patients with major depressive disorder and bipolar depression, when added to mood stabilizers like lithium or valproate to mitigate manic switch risk 14

Standard Dosing Protocol

• The standard dose of IV ketamine is 0.5 mg/kg infused over 40 minutes, although alternative slower infusion rates, such as 0.5 mg/kg over 100 minutes, may provide similar efficacy with potentially better tolerability 15
• Lower doses, such as 0.2 mg/kg, have shown efficacy in emergency department settings for suicidal ideation, though this is less studied for general depression treatment 16

Serial Infusion Protocol

• Twice weekly infusions until remission is achieved or 4-6 total infusions are completed is a common frequency for acute phase treatment, with response assessment evaluating for 50% reduction in depressive symptoms at 24 hours post-infusion 15, 16
• Alternative schedules, such as three times per week for 2 weeks, have been studied 16

Antisuicidal Effects

• IV ketamine has rapid antisuicidal effects, beginning at 40 minutes, with the largest effect sizes in patients with high-baseline suicidal ideation 14, 16
• Antisuicidal effects can persist for up to 10 days following a single infusion 16, 17
• The antisuicidal effects of IV ketamine may be partially independent of its general antidepressant effects 17

Rapid-Acting Antidepressants for Severe Depression

Comparison with Traditional Antidepressants

• Traditional antidepressants like venlafaxine require weeks to months for therapeutic effect and do not provide rapid relief, whereas ketamine can provide rapid symptom reduction, making it a more suitable option when rapid symptom reduction is the primary goal 18
• Even ECT, considered the most highly efficacious antidepressant treatment, may not provide reduction in suicidal ideation for 1-2 weeks, highlighting the need for rapid-acting antidepressants like ketamine 18